Quick Facts

• Support for Erectile Function: Avigra helps adult men achieve and maintain an erection adequate for sexual activity.
• Management of Pulmonary Arterial Hypertension (PAH): The medication supports the ability to exercise and may assist in delaying disease progression in adults with PAH.

---

Avigra is a prescription medication with established applications in two main therapeutic areas. The primary use is the management of erectile dysfunction (ED), a condition where a man is unable to get or sustain a penile erection suitable for satisfactory sexual performance. In this context, Avigra works to support the natural process that occurs during sexual stimulation, which may lead to increased blood flow to the penis.

The medication is also indicated for the treatment of Pulmonary Arterial Hypertension (PAH), a type of high blood pressure affecting the arteries in the lungs. In patients with PAH, Avigra may help to improve their ability to exercise and may assist in delaying the worsening of the condition. Treatment goals focus on supporting overall patient wellness in these specific indicated conditions.

Official Eligibility and Contraindications for Avigra

Avigra (Sildenafil) is a prescription medicine with specific rules regarding who can and cannot use it, as defined by regulatory authorities.

Contraindicated Populations (Must Not Use):

• Patients using organic nitrates (e.g., nitroglycerin) or guanylate cyclase stimulators (e.g., Riociguat) due to the risk of severe hypotension.
• Individuals with known hypersensitivity to sildenafil or any component of the tablet.
• Men for whom sexual activity is inadvisable due to severe cardiovascular issues like unstable angina or recent history of stroke or myocardial infarction.
• Patients with severe hepatic impairment (liver disease), hypotension (blood pressure <90/50 mmHg), or a history of Non-Arteritic Anterior Ischaemic Optic Neuropathy (NAION).

Age and Condition-Based Eligibility:

Population Status	Eligibility Rule
Approved Age	Adult men ge 18 for ED; Adults and children ge 1 for PAH.
Organ Impairment	Severe renal impairment or non-severe hepatic impairment requires conditional use with a dose adjustment consideration. Severe hepatic impairment is a contraindication.
Conditional Use	Caution is advised in patients with conditions predisposing to priapism (e.g., sickle cell anemia) or those taking alpha-blockers concurrently.
Sex Eligibility	Not indicated for use in female patients for the ED indication.

Official regulatory documents establish these criteria to define who is absolutely prohibited from using the medicine and who requires specific caution due to underlying health factors.

Interactions with other Medicines and Products

Avigra (Sildenafil) possesses officially documented interactions primarily involving two mechanisms: the potentiation of vasodilatory effects and the alteration of its metabolism. All interaction statements are derived strictly from government regulatory documents, such as the FDA Prescribing Information and the European Summary of Product Characteristics (SmPC).

Formal Restrictions and Contraindicated Combinations

Co-administration with organic nitrates or nitric oxide donors in any form is contraindicated. This is a pharmacodynamic interaction leading to a dangerous potentiation of hypotensive effects. Co-administration with the Guanylate Cyclase (sGC) stimulator riociguat is also formally contraindicated due to the risk of symptomatic hypotension.

Pharmacokinetic and Pharmacodynamic Interactions

Avigra's clearance is primarily dependent on the Cytochrome P450 (CYP) 3A4 enzyme. Substances classified as potent CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) reduce Sildenafil clearance, significantly increasing the drug's systemic exposure (Cmax and AUC). Conversely, CYP3A4 inducers (e.g., bosentan) decrease exposure. Alpha-blockers and other antihypertensives carry an officially documented risk of an additive blood pressure lowering effect. This risk of symptomatic hypotension is most likely to occur within the 4-hour window following Sildenafil administration. Furthermore, the consumption of Grapefruit juice, a weak CYP3A4 inhibitor, may cause modest increases in plasma levels, and alcohol is noted for its potential to contribute to hypotensive effects.

Avigra's mechanism is based on the potentiation of a natural biochemical signal within specific vascular tissues, resulting in an increase in localized blood flow.

Targeted Inhibition of the PDE5 Enzyme

Avigra's primary action is the selective, competitive inhibition of the Phosphodiesterase type 5 (PDE5) enzyme. This enzyme is chiefly responsible for the hydrolysis of the second messenger molecule cyclic Guanosine Monophosphate (cGMP). By blocking PDE5, the mechanism prevents cGMP's breakdown, leading to its accumulation inside smooth muscle cells.

️ Potentiation of Endogenous Vasodilation

The drug acts as a potentiator of the natural Nitric Oxide (NO) / cGMP signaling pathway. The inhibition of PDE5 sustains elevated cGMP levels only when the upstream signal, Nitric Oxide, is released physiologically. This cascade ultimately triggers the relaxation of the smooth muscle tissue lining the targeted blood vessels. The resulting sustained smooth muscle relaxation causes localized vasodilation (widening of the vessels), which produces the increase in regional blood flow into the targeted capillary networks.

Avigra (Sildenafil) is administered through two officially approved methods: the oral route as a tablet or reconstituted suspension, and the intravenous (IV) route for temporary use in the context of Pulmonary Arterial Hypertension (PAH). The general principle of its use is strictly defined by the intended indication.

For Erectile Dysfunction (ED), the medicine is used intermittently, as needed, not to exceed one dose per day. The typical starting dose is 50 mg oral, which may be adjusted within a range of 25 mg to a maximum of 100 mg. The tablet is generally administered one hour before anticipated activity, although the official window for use ranges from 30 minutes to 4 hours prior. The oral form may be taken with or without food.

Conversely, the use of Sildenafil for PAH is a scheduled, continuous treatment. This regimen requires administration three times a day (TID), with standard oral doses set at 20 mg TID, taken 4 to 6 hours apart. The 10 mg IV injection is administered TID only when the oral form is temporarily unfeasible. The official prescribing information recommends starting with a lower 25 mg dose for ED in older adults and those with severe hepatic or renal impairment, strictly defining the standardized approach to initial dosing in these populations.

Research evidence / Overview of Studies for Avigra

The research exploring Avigra for Erectile Dysfunction (ED) involved multiple short-term, randomized, placebo-controlled trials (RCTs). This research design explores outcomes and measures differences between a group receiving the medication and a group receiving an inactive treatment (placebo). Researchers examined outcomes related to patient-reported experiences of function, using specialized questionnaires to measure a man's ability to attain and maintain an erection adequate for sexual activity. Studies also monitored outcomes describing episodic or acute changes by tracking the frequency of successful intercourse attempts reported by participants over defined short periods. The core efficacy trials are generally short-term, and evidence is limited when comparing Avigra directly against other available active treatments for ED in long-term controlled studies.

---

Evidence for use in Pulmonary Arterial Hypertension (PAH)

Research for Pulmonary Arterial Hypertension (PAH) involved intermediate-term randomized trials focusing on adult patients. The research examined outcomes related to daily functioning or activity level. A key measure used in these trials was the 6-Minute Walk Distance (6MWD), which assesses a patient's exercise capacity over a defined period. Studies also monitored endpoints such as events that define clinical worsening, which is a composite measure including hospitalization or the need to start other treatments. Controlled trials reported measurements of exercise capacity and functional status, with some findings observed to be different when comparing the active groups to the placebo group.

Research in Special Populations

Specific research was studied for the pediatric population (children aged 1 to 17 years) with PAH. However, an important finding from one long-term study in children showed an unexpected pattern of increased mortality at higher doses. Because of this, the interpretation of the research and the overall evidence for use in children can differ across various global health authorities, and the risks and benefits in this specific group remain uncertain.

---

The Overall Evidence Quality and Areas of Uncertainty

The clinical evaluation of Avigra is primarily based on well-designed randomized trials. Nevertheless, certain areas of the evidence remain less established, and long-term effects are not fully established in all contexts. Comparative evidence is lacking from dedicated randomized studies designed to directly compare Avigra's performance against other available active treatments for either ED or PAH. Also, the question of whether the medication affects long-term prognosis for adult patients with PAH requires further ongoing research. The results apply only to the populations studied in the trials, and research does not determine whether an individual will respond similarly.

Key Studies & References

1. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction

Common questions about Avigra (FAQ)

Q: What is Avigra used for?

Avigra is a prescription medication primarily used to treat erectile dysfunction (ED) in men. It works by increasing blood flow to the penis to help a man get and keep an erection when he is sexually aroused.

Q: How should I take Avigra?

Take Avigra by mouth as needed, generally 30 minutes to 4 hours before sexual activity. You should not take it more than once per day. It can be taken with or without food, but taking it after a high-fat meal may cause the drug to take effect more slowly.

Q: What are the common side effects of Avigra?

Common side effects may include:

• Headache
• Flushing (reddening and warming of the face)
• Stomach upset or indigestion
• Nasal congestion
• Back pain or muscle pain
• Dizziness

These side effects are usually mild and temporary.

Q: Can women take Avigra?

No, Avigra is not approved for use in women. The safety and effectiveness of Avigra in women have not been established.

Q: Is Avigra safe to take with other medications?

Avigra can interact with several medications, which may cause serious side effects. It is very important to tell your doctor about all the medicines you take, especially:

• Nitrates (e.g., nitroglycerin, isosorbide mononitrate/dinitrate), often used for chest pain. Taking Avigra with nitrates can cause a dangerous drop in blood pressure.
• Alpha-blockers (used to treat high blood pressure or prostate problems).
• Other ED treatments.

Your doctor will determine if Avigra is safe for you based on your current medications and health condition.

Q: What should I do if I miss a dose?

Avigra is typically taken only as needed before sexual activity, so you do not have a regular dosing schedule to miss. If you are taking it for another approved condition with a regular schedule, take the missed dose as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and resume your regular schedule. Do not take two doses at the same time.

How to Store and Dispose of Avigra

To ensure product stability and safety, Avigra (Sildenafil) tablets must be stored according to specific regulatory requirements.

Official Storage Requirements

Detail	Requirement
Temperature	Store at controlled room temperature, 20 C to 25 C ( 68 F to 77 F).
Protection	Keep the tablets in the original container to protect them from light and moisture.
Child Safety	Store the medication out of the sight and reach of children.

Disposal Instructions

Disposal must adhere to pharmaceutical waste handling regulations. Do not discard unused or expired Avigra tablets in household waste or wastewater. Instead, dispose of the product in accordance with local requirements, which often involve returning the medicine to a designated collection point or pharmacy take-back scheme.